信立泰SAL0140获临床试验批准通知书

Core Viewpoint - Recently, the company received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0140 for the treatment of chronic kidney disease (CKD) [1] Group 1: Company Developments - The company announced that SAL0140 is a proprietary aldosterone synthase inhibitor [1] - The drug is intended to target indications including uncontrolled hypertension (including resistant hypertension), primary hyperaldosteronism, and chronic kidney disease (CKD) [1]